What is First Tracks Biotherapeutics Inc's stock-based comp?

First Tracks Biotherapeutics Inc (TRAX) reported stock-based comp of $11.5M in Q1 2026.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Screener

Jaguar UraniumJAGU

$866.94K+175%

GPA

General Purpose Acquisition Corp.GPAC

$1.51M-48.9%

VeradermicsMANE

$5.26M+2,369%

Polaryx Therapeutics, Inc.PLYX

$467K-89.5%

TargetTGT

$54M-21.7%

Dollar GeneralDG

$37.03M+22.3%

Reported directly by First Tracks Biotherapeutics Inc in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.

(in thousands)	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Net loss	$(50,484)	$(47,196)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	125	146
Stock-based compensation	11,503	7,746
Accretion/amortization of investments, net	(8)	(1,667)
Amortization of right-of-use assets – operating	—	460
Changes in operating assets and liabilities:
Prepaid expenses and other assets	2,157	(443)

Item 1. Combined Financial Statements.

What is First Tracks Biotherapeutics Inc's stock-based comp?: First Tracks Biotherapeutics Inc (TRAX) reported stock-based comp of $11.5M in Q1 2026.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Connect your AI assistant and compare it to peers, right in your chat.